PMID- 30786773
OWN - NLM
STAT- MEDLINE
DCOM- 20200311
LR  - 20221207
IS  - 1525-6006 (Electronic)
IS  - 1064-1963 (Linking)
VI  - 42
IP  - 1
DP  - 2020
TI  - Associations of homocysteine status and homocysteine metabolism enzyme 
      polymorphisms with hypertension and dyslipidemia in a Chinese hypertensive 
      population.
PG  - 52-60
LID - 10.1080/10641963.2019.1571599 [doi]
AB  - Background: Hypertension (HTN), dyslipidemia and hyperhomocysteinemia (HHcy) are 
      risk factors for cardiovascular disease (CVD).Methods: Hypertensive Chinese 
      subjects (n = 228) were enrolled. MTHFR C667T, MTHFR A1298C, MTR A2756G, and MTRR 
      A66G genotypes were determined. Unconditional logistic regression was performed 
      to determine the associations of serum Hcy status and genotypes with HTN and 
      dyslipidemia.Results: The mean age of hypertensive adults was 65.53 +/- 9.94 years, 
      including 88 (38.6%) men and 140 (61.4%) women. Patients with MTHFR 667TT and 
      MTRR GG carriers showed higher serum Hcy levels (P = 0.019 and 0.018, 
      respectively), which is associated with higher serum triacylglycerols (TAG) and 
      total cholesterol (TC) levels (P = 0.014 and 0.044, respectively) and a higher 
      risk for hypertriglyceridemia (OR = 1.889, 95% CI: 1.105-3.229, P = 0.020). 
      Compared with low Hcy and MTRR 66AA, those with high Hcy and 66AA or 66AG+GG 
      showed higher odd\s of hypertriglyceridemia (MTRR 66AA+ high Hcy: OR: 2.692, 95% 
      CI: 1.189-6.096, Pcombined = 0.018; MTRR 66AG/GG+ high Hcy: OR: 3.433, 95% CI: 
      1.517-7.772, Pcombined = 0.003, respectively). Patients with high Hcy and MTHFR 
      667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of 
      uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, 
      Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, 
      Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.Conclusions: 
      Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR 
      A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
FAU - Yuan, Xiaojie
AU  - Yuan X
AD  - Department of Epidemiology, School of Public Health, Air Force Medical 
      University, Xi'an, Shaanxi province, China.
FAU - Wang, Tingcai
AU  - Wang T
AD  - Department of chronic disease control, Gansu Provincial Centre for Disease 
      Control and Prevention, Lanzhou, Gansu province, China.
FAU - Gao, Jie
AU  - Gao J
AD  - Department of Epidemiology, School of Public Health, Air Force Medical 
      University, Xi'an, Shaanxi province, China.
FAU - Wang, Yunchao
AU  - Wang Y
AD  - School of Public Health, Gansu University of Traditional Chinese Medicine, 
      Lanzhou, Gansu province, China.
FAU - Chen, Yajun
AU  - Chen Y
AD  - School of Public Health, Gansu University of Traditional Chinese Medicine, 
      Lanzhou, Gansu province, China.
FAU - Kaliannan, Kanakaraju
AU  - Kaliannan K
AD  - Laboratory for Lipid Medicine and Technology, Department of Medicine, 
      Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
FAU - Li, Xiaochun
AU  - Li X
AD  - Department of chronic disease control, Center of disease control of Wuwei, Wuwei, 
      Gansu province, China.
FAU - Xiao, Jing
AU  - Xiao J
AD  - Department of chronic disease control, Center of disease control of Wuwei, Wuwei, 
      Gansu province, China.
FAU - Ma, Tianyou
AU  - Ma T
AD  - Institute of Endemic Diseases, Environment and Diseases-related Gene of Key 
      Laboratory of Education Ministry, Medical School of Xi'an Jiaotong University, 
      Xi'an, Shaanxi province, China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Epidemiology, School of Public Health, Air Force Medical 
      University, Xi'an, Shaanxi province, China.
FAU - Shao, Zhongjun
AU  - Shao Z
AD  - Department of Epidemiology, School of Public Health, Air Force Medical 
      University, Xi'an, Shaanxi province, China.
LA  - eng
PT  - Journal Article
DEP - 20190220
PL  - England
TA  - Clin Exp Hypertens
JT  - Clinical and experimental hypertension (New York, N.Y. : 1993)
JID - 9305929
RN  - 0 (Triglycerides)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 935E97BOY8 (Folic Acid)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 1.18.1.- (methionine synthase reductase)
RN  - EC 1.18.1.2 (Ferredoxin-NADP Reductase)
RN  - EC 1.5.1.20 (MTHFR protein, human)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
SB  - IM
MH  - Aged
MH  - Asian People/genetics
MH  - Cholesterol/blood
MH  - Female
MH  - Ferredoxin-NADP Reductase/*genetics
MH  - Folic Acid
MH  - Heterozygote
MH  - Homocysteine/*blood
MH  - Humans
MH  - Hypertension/blood/*genetics
MH  - Hypertriglyceridemia/blood/*genetics
MH  - Male
MH  - Methylenetetrahydrofolate Reductase (NADPH2)/*genetics
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Risk Factors
MH  - Triglycerides/blood
OTO - NOTNLM
OT  - Homocysteine
OT  - blood pressure
OT  - hypertension
OT  - serum lipids
OT  - single nucleotide polymorphisms
EDAT- 2019/02/23 06:00
MHDA- 2020/03/12 06:00
CRDT- 2019/02/22 06:00
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2020/03/12 06:00 [medline]
PHST- 2019/02/22 06:00 [entrez]
AID - 10.1080/10641963.2019.1571599 [doi]
PST - ppublish
SO  - Clin Exp Hypertens. 2020;42(1):52-60. doi: 10.1080/10641963.2019.1571599. Epub 
      2019 Feb 20.